NASDAQ:INBS News 31 December 2025 - 2 January 2026

NEW YORK, Jan 2, 2026, 11:40 ET — Regular session Shares of Intelligent Bio Solutions Inc slid on Friday as investors digested the micro-cap medtech company’s $10 million private placement announced late Wednesday. The stock was down 12.1% at $8.38 by 11:25 a.m. ET. Benzinga The pullback comes after the stock more than doubled on Dec. 31 following news of a manufacturing partnership aimed at scaling production of its fingerprint-based drug screening reader. Nasdaq The timing matters because INBS is trying to ramp production and shore up supply as it targets a 2026 U.S. market entry, while also tapping capital

NEW YORK, January 1, 2026, 03:10 ET — Market closed Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in the session. The financing lands as the micro-cap medtech company pitches a faster path to scale for its fingerprint-based drug screening reader, with management pointing to lower production costs and higher profitability ahead of a planned U.S. market entry. Private placements are a common funding route for small companies, but they can dilute existing shareholders — meaning each share represents

NEW YORK, December 31, 2025, 13:04 ET — Regular session Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock was up $6.56, or about 160%, at $10.66 by 1:04 p.m. ET. Google The announcement matters now because Intelligent Bio is trying to improve its unit economics as it scales. The company said the partnership should drive annual production cost savings of more than 40%, translating to an expected improvement of about 20 percentage points in gross margin. Gross margin